Researchers found combining immunotherapy with radiotherapy helps the immune system target and destroy cancer cells resistant to initial treatment. This approach improved survival rates and protected mice against disease recurrence.
Researchers have found a targeted treatment, afatinib, that can stop the growth of aggressive womb cancer cells and shrink tumours. The drug targets faults in the HER2 gene, which lie at the heart of the cancer cells, offering new hope for patients with this rare but deadly form of cancer.
Researchers at Cancer Research UK found that blocking a chemical signal produced by macrophages can shrink melanoma tumors and make them easier to treat. This discovery suggests that targeting this 'survival signal' could lead to new ways to treat the disease, which is responsible for around 13,300 deaths in the UK each year.
A third of women in the UK breast screening program do not fully understand the risks of 'overdiagnosis', despite being informed about the concept. Research found that intentions to attend screening remained high despite uncertainty about the information provided.
Acral melanomas, which affect the hands and feet, have unique DNA damage patterns not caused by UV radiation. Researchers sequenced tumor samples and found distinct genetic faults driving this rare skin cancer. Understanding these faults may lead to better treatments for acral melanoma.
Researchers at Cancer Research UK have found a new use for an old drug, rapamycin, in shrinking and stopping the spread of a specific type of pancreatic cancer tumour. The study suggests that targeting mTOR dependency may be a key to tailoring treatment to individual patients.
A study published in the British Journal of Cancer found that bladder cancer patients with high levels of the protein HIF-1α are more likely to benefit from a treatment called CON, which makes radiotherapy more effective. High levels of the protein were linked to better survival rates when patients had radiotherapy and CON.
Scientists at Barts Cancer Institute have identified a molecule called focal adhesion kinase (FAK) that signals the body to repair itself after chemotherapy or radiotherapy. Removing FAK from blood vessels in melanoma and lung cancer models made treatments more effective, suggesting that targeting this molecule could boost cancer therapy.
Researchers found that fast-growing melanoma cells 'piggy-back' with invasive cells to establish new tumors, increasing the disease's deadly potential. The discovery could lead to new treatments for aggressive melanoma.
Researchers found no difference in cancer incidence between those living near nuclear power plants and the general population. The study confirms raised risks of cancer, particularly leukaemia, for earlier time periods.
Researchers reveal detailed images of anaphase-promoting complex (APC/C), a protein that controls mitosis. The discovery could lead to new cancer drugs by identifying binding sites for future treatments.
A study found that trials with broader age limits resulted in a significant increase in teenage cancer patients participating in clinical trials. The study showed a 13% rise in 15-19 year old patients and a 5% rise in 20-24 year olds, as well as an increase in children under 14 taking part in trials.
Cancer Research UK's Programme Foundation Award will provide up to £1.5 million over six years to support mid-career scientists. The award aims to bridge the gap for researchers who need investment to compete with senior scientists.
Researchers at Cancer Research UK Manchester Institute have found that blocking the MLK family of four enzymes can prevent rapid resistance to vemurafenib, a treatment for advanced melanoma. This breakthrough could lead to new targeted therapies for metastatic melanomas with limited treatment options.
Researchers have discovered a new role for Cullin-5 in killing cancer cells by targeting proteins that drive cell division. The study suggests a possible test to identify responsive patients and develop more effective drugs.
A pioneering clinical trial will test multiple drugs simultaneously in patients with advanced lung cancer based on their genetic profile. The 'National Lung Matrix' trial aims to provide more personalized treatment options for cancer patients.
Scientists have discovered that high iron levels can cause bowel cancer in people with a faulty gene, increasing the risk by two to three times. A diet low in iron prevents bowel cancer from developing altogether.